Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/09/22
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 07/27/22
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical OfficerPRNewsWire • 07/05/22
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/10/22
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022PRNewsWire • 04/29/22
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis PatientsPRNewsWire • 04/25/22
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring FridayInvestorPlace • 04/08/22
Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 03/09/22
Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis PatientsPRNewsWire • 02/28/22
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis PatientsBenzinga • 01/24/22
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis PatientsPRNewsWire • 01/24/22
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 11/09/21